The RRI Group of Companies Expands Device & Pharmaceutical Capabilities

Lake Wylie, SC, April 10, 2009 --(PR.com)-- George Gessner, Dr. Loren Gelber, and Dr. Greg Maguire, principals in The RRI Group of Companies, announced today the addition of four associate members to The RRI Group who will further strengthen RRI’s ability to lead clients through the FDA approval process for devices and pharmaceuticals. Today, said George Gessner, “The RRI Group of Companies has added four new members to our present 18 associate’s who will enhance our services in device and pharmaceutical development, including the development of intellectual property (IP).”

Dr. Maguire added, “Our new associates are:

Robert Mazzaferro who has a graduate degree in engineering and is an ex-FDA reviewer for devices,

Uli Foley with years of experience in devices and pharmaceuticals, including product launches and business to business partnerships,

Dr. Dennis Babel a leading mycologist with world-wide experience in clinical trial management and training, as well as,

Samer Hindiyh, J.D. who is our Patent Director with several years of experience in all ranges of patents and copyrights, as well as hands on experience in developing several business partnerships resulting in symbiotic growth for all parties involved.”

Dr. Loren Gelber elaborated that “These four outstanding specialist join RRI’s other associates in our day to day dealings with the FDA, including Charles Bon, a noted biostatistician with extensive experience in study design, along with Robert Zeid who has years of experience in the pre-IND, IND, NDA processes.” Mr. Gessner further stated “RRI is well known for its success in bringing 505(b)(2) NDA’s through the approval process, but is also leading several clients through the FDA approval process for devices, and with this expansion we will now better serve our clients in need of approval through the 510K and PMA regulatory paths.”

###